Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Faeth Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 25 | 24 | −1 |
| Shares | 2.31M | 2.11M | −201.6K (−8.7%) |
| Value | $2.43M | $1.31M | −$1.12M (−46.1%) |
New holders (5)
Institutions that held Faeth Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 650,000 | $403.1K | 0.13% |
| Boothbay Fund Management, LLC | 172,835 | $107.2K | 0.00% |
| Two Sigma Securities, LLC | 18,600 | $11.5K | 0.00% |
| XTX Topco Ltd | 14,047 | $8.71K | 0.00% |
| National Bank of Canada | 10,000 | $5.90K | 0.00% |
Sold out (6)
Institutions that held Faeth Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Newtyn Management, LLC | 930,230 | $976.7K |
| Millennium Management LLC | 32,587 | $34.2K |
| Two Sigma Advisers, LP | 19,000 | $19.9K |
| Two Sigma Investments, LP | 10,176 | $10.7K |
| UBS Group AG | 139 | $146 |
| Wells Fargo & Company | 133 | $140 |